Splendris Pharmaceuticals GmbH is interested in license-in the following medicinal products for human health.
Our partnership model is highly flexible. We are interested in products, marketing authorisations, dossiers, and the technology of formulation and/or APIs.
- Cefuroxime Axetil Tablets (124 mg, 250 mg)
- Clopidogrel/Acetylsalicylic Acid Entero Tablets (75 mg/75 mg, 75 mg/100 mg)
- Dapoxetine Tablets (30 mg, 60 mg)
- Erlotinib Tablets (100 mg, 150 mg)
- Ezetimible Tablets (10 mg)
- Ezetimibe/Simvastatin Tablets (10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg)
- Fluvastatin Extended Release Tablets (80 mg)
- Imatinib Tablets (100 mg, 400 mg)
- Ivabradine Tablets (5 mg, 7.5 mg)
- Levetiracetam Injection (500 mg/5 ml)
- Levetiracetam Oral Solution (100 mg/ml)
- Lercanidipine Tablets (10 mg)
- Moxifloxacin Tablets (400 mg)
- Pitavastatin Tablets (1 mg, 2 mg)
- Olmesartan Tablets (20 mg)
- Rosuvastatin Tablets (5 mg, 10 mg, 20 mg, 40 mg)
- Valsartan Tablets (40 mg, 80 mg, 160 mg, 320 mg)
Contact us now online: contact form.
